Alkermes (ALKS)
NASDAQ: ALKS
· Real-Time Price · USD
30.16
-0.22 (-0.72%)
At close: May 09, 2025, 3:59 PM
30.01
-0.50%
Pre-market: May 12, 2025, 07:15 AM EDT
Alkermes Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Aristada And Aristada Initio Revenue | 346.19M | 327.69M | 302.05M | 275.36M | 524.5M | 302.61M |
| Aristada And Aristada Initio Revenue Growth | +5.64% | +8.49% | +9.70% | -47.50% | +73.33% | n/a |
| L Y B A L V I Revenue | 280.03M | 191.89M | 96.02M | 8.21M | 335.37M | n/a |
| L Y B A L V I Revenue Growth | +45.93% | +99.84% | +1068.86% | -97.55% | n/a | n/a |
| Product Revenue | 1.08B | 920M | 777.55M | 627.42M | n/a | n/a |
| Product Revenue Growth | +17.78% | +18.32% | +23.93% | n/a | n/a | n/a |
| Vivitrol Revenue | 457.31M | 400.42M | 379.48M | 343.85M | n/a | n/a |
| Vivitrol Revenue Growth | +14.21% | +5.52% | +10.36% | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 171.7M | 146.99M | 150.38M | 168.11M | 179.75M | 140.57M | 156.37M | 195.76M | 167.83M | 157.54M | 152.78M | 150.38M | 145.05M | 160.41M | 136.21M | 139.19M | 125.17M | 145.78M | 127.65M | 132.03M | 133.37M | 154.45M | 148.7M | 155.07M | 141.22M | 141.23M | 128.78M | 138.26M | 118.15M | 110.9M | 99.63M | 108.95M | 102.1M | 97.14M | 91.14M | 96.12M | 89.72M | 87.47M | 89.5M | 71.54M | 63.05M |
| Selling, General, and Administrative Revenue Growth | +16.81% | -2.25% | -10.55% | -6.47% | +27.87% | -10.11% | -20.12% | +16.64% | +6.53% | +3.12% | +1.60% | +3.67% | -9.57% | +17.76% | -2.14% | +11.20% | -14.14% | +14.20% | -3.31% | -1.01% | -13.65% | +3.87% | -4.11% | +9.81% | 0.00% | +9.67% | -6.86% | +17.02% | +6.54% | +11.30% | -8.55% | +6.71% | +5.10% | +6.58% | -5.18% | +7.14% | +2.57% | -2.26% | +25.10% | +13.46% | n/a |
| Research and Development Revenue | 71.82M | 56.67M | 59.89M | 59.65M | 67.61M | -20.76M | 64.88M | 68.22M | 63.77M | 104.59M | 100.43M | 92.87M | 95.95M | 98.37M | 118.41M | 97.47M | 92.27M | 112.11M | 94.98M | 94.22M | 93.28M | 198.16M | 107.67M | 104.44M | 102.57M | 108.97M | 101.27M | 106.82M | 108.35M | 104.49M | 104.41M | 99.15M | 104.83M | 89.63M | 99.44M | 97.01M | 101.07M | 93.69M | 92.56M | 87.88M | 70.28M |
| Research and Development Revenue Growth | +26.72% | -5.37% | +0.41% | -11.78% | -425.69% | -132.00% | -4.91% | +6.99% | -39.03% | +4.14% | +8.14% | -3.21% | -2.46% | -16.92% | +21.48% | +5.64% | -17.70% | +18.03% | +0.80% | +1.01% | -52.93% | +84.04% | +3.10% | +1.82% | -5.87% | +7.61% | -5.20% | -1.41% | +3.69% | +0.08% | +5.30% | -5.42% | +16.97% | -9.87% | +2.51% | -4.02% | +7.88% | +1.22% | +5.32% | +25.05% | n/a |